2026 04 21 Unitedhealth UNH Q1 2026 Earnings Call
MCR improved to 83.9% on pricing discipline + reserve development; OptumHealth turnaround through clinical management; GLP-1 Medicare path 'find a way to yes' but structural challenges remain.
view source ↗Summary
UnitedHealth reported a Q1 2026 recovery: MCR improved from 84.8% to 83.9%, driven by pricing discipline and $500M+ favorable reserve development. OptumHealth is executing a clinical management turnaround (35% reduction in skilled nursing admissions in one region). Management guided "above $18.25" full-year EPS with "prudent patience" signaling cautious conservatism. On GLP-1 drugs, management committed to "find a path to yes" on Medicare's Balance Program but flagged structural challenges in the current framework.
Transcript
Tim Noel (CEO, UnitedHealthcare): "Pricing is improving relative to elevated health care cost trends" with management taking "disciplined pricing actions" that enabled margin recovery despite persistent medical cost pressures.
Wayne DeVeydt (CFO): MCR improved to 83.9% from 84.8%, attributing this to "pricing discipline, strong medical cost management, and favorable reserve development" totaling "a little bit north of $500 million" in prior period development.
Krista Nelson (President, UnitedHealthcare): Performance improvements came from "intentional actions" including clinical management focus. In one region, they achieved "an approximately 35% reduction in skilled nursing admissions" through data-driven navigation.
Bobby Hunter: Management would "find a path to yes" on Medicare's Balance Program for GLP-1 drugs but noted "some notable challenges and outstanding questions with the currently planned structure."
Wayne DeVeydt (CFO): Management raised full-year guidance to "above $18.25" EPS while emphasizing "prudent patience" given it's "still early in the year," signaling measured expectations for remaining quarters.